A Pilot Study of Nintedanib in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Jul 2017 Planned End Date changed from 31 Dec 2017 to 30 Jun 2018.
- 20 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Dec 2017.
- 10 Jun 2017 Biomarkers information updated